China's first Ginkgo ester B single institutional agent enters Phase II clinical

the research and development of Ginkgo preparations in China and spread the newsRecently, the reporter learned from Guangdong Agricultural Industry and Commerce Group, the group's backbone enterprises Guangzhou Huacheng Pharmaceutical Factory and the Chinese People's Liberation Army GeneralHospital, Hefei University of Technology jointly developed the world's only Ginkgo monomer injection - silver ester blood injection has entered phase II clinical trials, which marks the independent intellectual property rights of Chinese medicine and other innovative drugs into the final stage of research and developmentIn 2004, Guangzhou Huacheng Pharmaceutical Factory identified the silver ester blood injection research and development projectIn the course of the project implementation, the United Nations in the natural drug purification technology leading Hefei University of Technology, new drug research and development and clinical technology leading Chinese the Pla GeneralHospital, to overcome the internal ester B monomer purification industrialization production technology, the development of a unique formulation process, the project has been included in the Guangdong ProvinceChinese medicinedevelopment of the "11th Five-Year Plan" of the famous enterprises, famous pharmaceutical projectsExperts say Ginkgo ester B single-regime agent for the treatment of cardiovasculardisease
, cerebral ischemia, brain aging, Alzheimer's disease and asthma has a unique effectWith the advent of an aging society, the prevalence ofofofdiseases such as cardiovascular diseases, such as cardiovascular and cerebrovascular diseases and Alzheimer's diseases has increased rapidly, and the demand for drugs to treat these diseases is increasing According to authoritative statistics, once the Ginkgo ester B monomer is listed, the domestic demand will exceed 40 million units per year Huacheng Pharmaceutical Factory said that the total investment in the research and development project is 145 million yuan, the new productis are expected to be launched in the second half of 2008, the company plans to the "11th Five-Year Plan" by the end of the sales revenue of 2 billion yuan Pictured is the site of the product presentation (reproduced from the Journal of Medicine and Economics)